2010
EFNS guidelines for the diagnosis and management of Alzheimers disease
HORT, J., JT. O BRIEN, G. GAINOTTI, T. PIRTTILA, BO. POPESCU et. al.Základní údaje
Originální název
EFNS guidelines for the diagnosis and management of Alzheimers disease
Název česky
EFNS doporučení pro diagnostiku a léčbu Alzheimerovy nemoci
Autoři
HORT, J. (203 Česká republika), JT. O BRIEN (826 Velká Británie a Severní Irsko), G. GAINOTTI (380 Itálie), T. PIRTTILA (246 Finsko), BO. POPESCU (642 Rumunsko), Irena REKTOROVÁ (203 Česká republika, domácí), S. SORBI (380 Itálie) a P. SCHELTENS (528 Nizozemské království, garant)
Vydání
European Journal of Neurology, 2010, 1351-5101
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30000 3. Medical and Health Sciences
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 3.765
Kód RIV
RIV/00216224:14110/10:00047014
Organizační jednotka
Lékařská fakulta
UT WoS
000281799200006
Klíčová slova anglicky
Alzheimers disease; dementia; diagnosis; guideline; management; review; treatment
Změněno: 20. 1. 2011 23:28, prof. MUDr. Irena Rektorová, Ph.D.
Anotace
V originále
The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non- Alzheimer dementias are not included in this guideline. Methods: The task force working group reviewed evidence from original research articles, meta-analysis, and systematic reviews, published before May 2009. The evidence was classified and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. Results: The recommendations for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of AD, behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers were all revised as compared with the previous EFNS guideline. Conclusion: A number of new recommendations and good practice points are made, namely in CSF, neuropsychology, neuroimaging and reviewing non-evidence based therapies. The assessment, interpretation, and treatment of symptoms, disability, needs, and caregiver stress during the course of AD require the contribution of many different professionals. These professionals should adhere to these guideline to improve the diagnosis and management of AD.
Návaznosti
MSM0021622404, záměr |
|